DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes

DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news

Related Links:

CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
TYPE 2 diabetes may feel like a minefield - can you eat this or that without spiking blood sugar levels? If you're feeling peckish, what's a good, healthy option for lunch?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Authors: Frías JP Abstract INTRODUCTION: The glucagon-like peptide-1 (GLP-1) receptor agonists (RA) have increasingly gained prominence in the treatment of type 2 diabetes (T2D) based on their glycemic benefits and favorable body weight and cardiorenal effects. Despite this, continued development of therapeutics with superior efficacy is important to help address persistent challenges in the attainment of metabolic goals in many patients with T2D. AREAS COVERED: Tirzepatide is an unimolecular dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA in development for the treatment of T2D. This re...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Type 2 diabetes mellitus (T2DM) represents a major health problem,1 contributing to 11.3% of deaths globally.2 Cardiovascular disease (CVD) still affects a large proportion of patients,3 despite the fact that incidence rates of cardiovascular outcomes have decreased over the last two decades.4 Heart failure (HF) is a main contributor of cardiovascular morbidity and mortality among patients with T2DM,5 who feature an almost twofold increase in the risk of HF, with women having a greater risk compared to men.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Conclusions: In this large cohort of adult patients with T2D and NAFLD, commonly used fibrosis scores had reasonable specificity, but poor sensitivity for detecting AF in diabetics. The development of reliable biomarkers for NAFLD/NASH in diabetics is urgently needed.
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: LIVER, PANCREAS & BILIARY TRACT: Original Articles Source Type: research
Conclusions: Treatment satisfaction does not change significantly in Japanese patients with T2DM who switch to GLY from the reference product or from insulin degludec. Safety and effectiveness over a 12-month period were similar in GLY-treated patients who switched from either insulin glargine or insulin degludec.ClinicalTrials.gov: Not applicable. PMID: 33030354 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Authors: Nguyen C, Luthra R, Kuti E, Willey VJ Abstract Background: Description of risk of cardiovascular (CV) events associated with diabetes is evolving. This US-based real-world study estimated risk of future CV events and heart failure (HF) from type 2 diabetes (T2DM)-only, prior CV events-only, or T2DM + prior CV events, versus controls, and evaluated healthcare resource utilization (HCRU) and costs.Methods and Materials: This retrospective cohort study queried claims and mortality data for 638,301 patients: T2DM-only (377,205); prior CV events-only (130,964); both T2DM + prior CV e...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
FRIDAY, Oct. 9, 2020 -- Patients with type 2 diabetes (T2D) are more likely to develop vascular dementia and nonvascular dementia compared with controls without diabetes, according to a study presented at the annual meeting of the European...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | SGLT2 Inhibitors